Fiduciary Alliance LLC Buys Shares of 49,567 Hims & Hers Health, Inc. (NYSE:HIMS)

Fiduciary Alliance LLC acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 49,567 shares of the company's stock, valued at approximately $1,465,000.

Other large investors also recently modified their holdings of the company. Crewe Advisors LLC acquired a new position in Hims & Hers Health in the 4th quarter valued at about $28,000. Blume Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 600 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after acquiring an additional 1,413 shares during the period. Summit Securities Group LLC acquired a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $38,000. Finally, US Bancorp DE increased its stake in shares of Hims & Hers Health by 346.7% during the fourth quarter. US Bancorp DE now owns 1,943 shares of the company's stock worth $47,000 after purchasing an additional 1,508 shares during the period. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Trading Down 1.7%

HIMS stock traded down $0.95 during mid-day trading on Wednesday, hitting $53.78. The stock had a trading volume of 60,326,153 shares, compared to its average volume of 20,386,679. The firm has a fifty day simple moving average of $40.77 and a 200 day simple moving average of $36.56. The firm has a market capitalization of $12.04 billion, a P/E ratio of 122.23 and a beta of 1.84. Hims & Hers Health, Inc. has a 52 week low of $13.47 and a 52 week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. During the same period last year, the firm posted $0.05 earnings per share. The firm's quarterly revenue was up 110.7% compared to the same quarter last year. As a group, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Soleil Boughton sold 3,233 shares of the stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $55.87, for a total value of $180,627.71. Following the completion of the transaction, the insider now owns 153,194 shares of the company's stock, valued at $8,558,948.78. This represents a 2.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Oluyemi Okupe sold 11,581 shares of the business's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $60.22, for a total transaction of $697,407.82. Following the sale, the chief financial officer now directly owns 113,816 shares in the company, valued at approximately $6,853,999.52. The trade was a 9.24% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 617,367 shares of company stock worth $25,227,888 over the last 90 days. Insiders own 13.71% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on HIMS. Needham & Company LLC boosted their price target on Hims & Hers Health from $61.00 to $65.00 and gave the company a "buy" rating in a research note on Wednesday. TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and dropped their target price for the stock from $44.00 to $30.00 in a report on Tuesday, April 29th. Piper Sandler reissued a "neutral" rating and issued a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Citigroup restated a "sell" rating and issued a $30.00 price target (up from $25.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Finally, UBS Group reiterated a "mixed" rating on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Hims & Hers Health has a consensus rating of "Hold" and a consensus price target of $38.00.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.